Fig. 2 | Scientific Reports

Fig. 2

From: Geriatric nutritional risk index and newly developed scoring system as prognosis prediction for unresectable hepatocellular carcinoma patients treated with lenvatinib

Fig. 2

Progression-free and overall survival of patients treated with lenvatinib (LEN) according to GNRI-C score. (a) Median progression-free survival (PFS) for a GNRI-C score of 0, 1, 2, and 3 was 10.79 (95% CI 8.71–12.82), 7.46 (95% CI 5.89–7.96), 5.75 (95% CI 3.93–6.82), and 3.68 (95% CI 2.75–5.07) months, respectively (p < 0.001). (b) Median overall survival (mOS) for a GNRI-C score of 0, 1, 2, and 3 was 28.61 (95% CI 22.93–35.75), 19.64 (95% CI 14.39–26.46), 10.25 (95% CI 8.54–14.89), and 8.21 (95% CI 4.76–10.21) months, respectively (p < 0.001).

Back to article page